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Abstract
Introduction: Globally, multidrug resistant tuberculosis (MDR-TB) remains underdiagnosed. The Genotype MTBDRplusH, a
rapid drug susceptibility testing (DST) assay used to detect resistance to isoniazid and rifampicin in the diagnosis of MDR-TB,
has good diagnostic accuracy, but its impact on patient outcomes in routine practice is unproven. We assessed the clinical
impact of routine DST using MTBDRplus in a single health district in South Africa.
Methods: Data were collected on all adult pulmonary TB patients registered at 25 public health clinics in the periods before
and after introduction of an expanded DST algorithm using MTBDRplus version 1.0.
Results: We collected data on 1176 TB patients before implementation and 1177 patients afterwards. In the before period,
measured MDR-TB prevalence among new cases was 0.7% (95% CI1.4–3.1%), and among retreatment cases 6.2% (95%
CI:3.5–8.8%), versus 3.7% (95% CI:2.4–5.0, p,0.01) and 6.6% (95% CI:3.8–9.4%, p = 0.83) respectively after MTBDRplus
introduction. The median times from sputum collection to MDR treatment in the before and after periods were 78 days
(IQR:52–93) and 62 days (IQR:32–86, p = 0.05), respectively. Among MDR-TB cases, 27% (95%CI:10–44) in the before period
converted sputum cultures to negative by 8 months following treatment initiation, while 52% (95%CI:38–66) converted in
the intervention period (p = 0.04).
Conclusions: The expanded use of MTBDRplus DST resulted in a substantial increase in the proportion of new cases
identified as MDR-TB; though time to MDR treatment was reduced, it was still over two months. Culture conversion for
MDR-TB patients improved after introduction of MTBDRplus. This work illustrates the mixture of successes and challenges
resulting from increased access to rapid DST in a setting with a high TB burden.
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Introduction
Diagnosis of multidrug resistant tuberculosis (MDR-TB) repre-
sents a barrier to TB control, as only 7% of the estimated 440,000
emerging cases worldwide in 2008 were detected [1]. Global
laboratory capacity for drug susceptibility testing (DST) to
diagnose MDR-TB remains low–in 2010, just 13 of the 27 high
MDR-TB burden countries reported at least 1 laboratory to
perform DST per 5 million people [2]. Timely diagnosis of MDR-
TB has the potential to improve treatment outcomes, reduce
mortality, and reduce transmission [3].
Culture-based DST methods are hampered by slow turnaround
times–culture on solid media can take 8–12 weeks for results, while
a liquid culture system, the BACTEC MGIT 960 (BD, Franklin
Lakes, NJ) has only reduced this timeframe to 3–4 weeks [4]. Line
probe assays (LPA) are molecular methods for DST that can be
performed directly on smear-positive sputum specimens or
cultured isolates. One commercially available LPA, MTBDRplus
version 1.0 (Hain LifeScience GmbH, Nehren, Germany), showed
excellent sensitivity and specificity for rifampin resistance (98.1%
and 98.7%, respectively) and lower accuracy for isoniazid
resistance (84.3% sensitivity and 99.5% specificity) in a recent
meta-analysis [5]. In a demonstration study set in a high-volume
South African clinical laboratory, DST results were available
within 1–2 days, with a total turnaround time of ,7 days [6]. The
MTBDRplus assay is technically complex and requires significant
laboratory resources including specialized instrumentation, highly
trained technicians, reliable electricity, and separate rooms for
extraction, amplification, and hybridization. In 2008, the WHO
endorsed the use of LPAs for DST as a rapid alternative to culture
[7].
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In 2009, South Africa introduced a new DST strategy, moving
from using MGIT-based phenotypic DST performed only for TB
patients with risk factors for MDR-TB, to using MTBDRplus on
all bacteriologically confirmed TB patients. The goal of the
present study was to evaluate the impact of this strategy change.
We present data collected in the course of routine TB program
operation in a single health district in South Africa from the
periods before and after the introduction of the expanded DST
algorithm using MTBDRplus version 1.0. We compared preva-
lence of drug resistance, uptake of DST, times to results and MDR
treatment, and culture conversion and mortality among MDR




We conducted a ‘‘before and after’’ cohort study in the Frances
Baard health district in Northern Cape Province, South Africa.
The expanded DST algorithm using MTBDRplus version 1.0, a
commercially available LPA, was instituted in September 2009.
Data on all newly registered adult (age $18 years) pulmonary TB
patients from 25 public health facilities within the district were
retrospectively collected through record reviews for two six-month
time periods: prior to the introduction of the expanded algorithm
from August 2007-January 2008 (the ‘‘Before LPA’’ period) and
afterwards, from October 2009-March 2010 (the ‘‘After LPA’’
period). DST algorithms for both periods are presented in Figure 1.
During the Before LPA period, DST was performed according to
the 2004 National TB Control Guidelines [8] using MGIT for TB
cases assessed by clinicians as being at high risk for MDR-TB.
During the After LPA period, DST was performed using
MTBDRplus on all TB cases with either a positive smear of grade
$ scanty 8 (defined as at least 8 acid fast bacilli per 100 oil
immersion fields [9]) or a positive MGIT culture.
Laboratory Testing
Laboratory testing was performed under routine program
conditions at the National Health Laboratory Services (NHLS)
TB referral laboratory in Kimberley, South Africa. Sputa were
collected according to TB program guidelines [8,10] and
couriered daily to the laboratory. Specimens were concentrated
via centrifugation and decontaminated using N-acetyl L-cysteine-
NaOH, before resuspension in phosphate buffer (pH 6.8). Fixed
smears were stained with auramine then examined with flores-
cence microscopy. Slides were graded according to the Interna-
tional Union Against Tuberculosis and Lung Disease scale [9].
MGIT tubes were inoculated using 0.5 mL of the digested,
resuspended sputum, and were incubated and read daily per
manufacturer instructions [11]. Cultures were considered negative
after 35 days without growth. Positive MGIT cultures were
examined for acid fast bacilli by Ziehl-Neelson staining.
During the Before LPA period, DST was performed upon
clinician request and according to manufacturer protocol on
positive MGIT cultures using the BD BACTEC SIRE Drug Kit
[12]. During the After LPA period, DST was performed using
MTBDRplus version 1.0 directly on sputum samples graded
$scanty 8, and on MGIT cultures from sputum samples
graded,scanty 8 or negative. Briefly, DNA was extracted from
1 mL of positive MGIT culture, or 0.5 mL of concentrated
resuspended sputum sample according to manufacturer’s protocol
[13]. Hybridization was done using the Hain Lifescience GT Blot
48. For MTBDRplus testing, resistance to isoniazid (INH) and
rifampin (RIF) were interpreted for samples positive for M.
tuberculosis complex. If resistance was indeterminate by
MTBDRplus, that test was repeated using the MGIT culture
isolate, if available. Strips with positive control bands and no band
for M. tuberculosis complex were reported as non-tuberculous
Mycobacteria, and no DST results were read or reported. Culture-
based DST was not performed in order to confirm MTBDRplus
findings. Laboratory test data were captured routinely using the
NHLS electronic data management system. Patient data abstract-
ed from clinic records were matched to laboratory data through
laboratory identification numbers and unique patient identifiers.
Statistical Analysis
Statistical analyses were conducted using Stata 11.2 (StataCorp
LP, College Station, TX). Standard descriptive statistics were used
to characterize the study population at TB diagnosis. Pearson’s
chi-square was used to compare categorical variables and the
Wilcoxon rank-sum test was used for continuous variables.
Kaplan-Meier curves were used to estimate time to MDR
treatment for MDR-TB patients. As the time to treatment during
the Before LPA period was likely an underestimate due to
unobserved times for undetected MDR cases, a simple model was
created to estimate the true time to appropriate treatment during
this period. In this model, during the Before LPA period,
individuals who did not have the outcome (MDR treatment) were
added to the population of MDR-TB cases and were censored
after six months spent on incorrect treatment. Estimates are
presented for data as collected as well as modeled data for this
study period.
Outcomes for MDR-TB patients were administratively cen-
sored at eight months following registration in order to ensure
comparable follow-up between the study periods. Culture conver-
sion among MDR patients was considered to be two consecutive
negative cultures, at least one month apart. Mortality among
MDR patients was estimated using Kaplan-Meier curves and
compared using the log-rank statistic.
Ethics Approval
This study was approved by the Johns Hopkins Medicine
(NA_00031006) and University of the Witwatersrand (M090679)
institutional review boards, and had the approval of the
Department of Health of the Northern Cape Province, Kimberley,
South Africa. The need for written informed consent was waived
by both review boards as participant information was gathered
solely through the review of existing medical records collected
during the course of routine patient care, the study carried
minimal risk to the participants, the data were analyzed
anonymously, and the study was conducted with a government
entity as operational research in order to evaluate an ongoing
public health program.
Results
Characteristics of the Study Population at TB Diagnosis
Overall, 3734 TB patients were recorded in the TB registries of
the 25 public health facilities–1826 (49%) in the Before LPA
period and 1908 (51%) in the After LPA period. During the Before
LPA period, 237 extrapulmonary (13%) and 413 pediatric cases
(22%) were excluded, while during the After LPA period, 229
extrapulmonary (12%) and 502 pediatric cases (26%) were
excluded. Characteristics of the remaining 2353 adult pulmonary
TB patients are presented in Table 1.
HIV testing of TB patients increased between study periods,
with 82% of patients in the Before LPA period having known HIV
status compared to 93% in the After LPA period (p,0.001). The
Impact of MTBDRplus in South Africa
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proportion of TB patients on antiretroviral therapy (ART) at TB
diagnosis increased from 18% (95% CI: 15–21) during the Before
LPA period to 29% (95% CI: 26–32) during the After LPA period
(p,0.001).
During the Before LPA period, culture was performed on 67%
of TB cases as part of the initial TB diagnostic workup, including
82% of smear negatives and 62% of smear positives. During the
After LPA period, use of culture increased to 80% of TB cases
(p,0.001), including 86% of smear negatives and 77% of smear
positives.
DST and MDR-TB during the Two Study Periods
After introduction of the expanded testing algorithm, DST was
more widely applied (Figure 2). During the Before LPA period,
251/1176 (21%, 95% CI: 19–23) TB cases had DST performed,
compared to 962/1177 (82%, 95% CI: 80–84) cases in the After
LPA period (p,0.001). Table 2 presents drug resistance by study
period. In the Before LPA period, 26 cases of MDR-TB were
identified among 1176 TB patients (2.2%, 95% CI: 1.4–3.1%). In
the After LPA, twice as many (52) cases were found among 1177
TB patients, for a prevalence of 4.5% (95%CI: 3.2–5.6%, p 0.003).
The increase in diagnosed MDR-TB cases was mainly among new
cases–during the After LPA period 3.7% (95%CI: 2.4–5.0) of new
cases had MDR-TB diagnosed, while during the Before LPA
period, only 0.7% (0.01–1.2%) of new cases had MDR-TB
detected (p,0.001). We also observed an increase in RIF and INH
mono-resistance between periods. During the Before LPA period,
2.4% (95%CI:1.5–3.3) of all cases were diagnosed with INH
mono-resistance, while in the After LPA period, 4.2%
(95%CI:3.0–5.3) were diagnosed (p = 0.015). During the Before
LPA period, 0.2% (95%CI:0–0.4) were diagnosed with RIF mono-
resistance, while 1.8% (95%CI:1.0–2.5) were diagnosed during the
After LPA period (p,0.001).
Test Turnaround Time and Time to MDR Treatment
Figure 3A presents a decomposition of the time to MDR
treatment. The median time from sputum collection to DST
results (Figure 3A, time period 2) during the After LPA period was
half that observed in the Before LPA period (Before LPA, 52 days
[IQR: 41–77]; After LPA, 26 days [IQR: 11–52 days]; p 0.008).
The median time from initial sputum collection to start of MDR
treatment during the Before LPA period was 78 days (IQR: 52–
93), and was significantly shorter during the After LPA period at
62 days (IQR: 32–86, p 0.045). For smear positive cases during the
After LPA period, the median time to MDR treatment was 54
days (IQR: 31–66), while during the Before LPA period, the
Figure 1. DST algorithm by study period. An illustration of the DST algorithm in the Before LPA period (A) and the After LPA period (B).
Abbreviations: DST, drug susceptibility testing; LPA, line probe assay; TB, tuberculosis; MDR-TB, multidrug resistant tuberculosis.
doi:10.1371/journal.pone.0049898.g001
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Table 1. Characteristics of all TB patients and MDR-TB patients at the time of TB diagnosis.
All TB Patients MDR-TB Patients
Characteristic Before LPA After LPA p-value* Before LPA After LPA p-value*
n (%) 1176 (50%) 1177 (50%) – 26 (33%) 52 (67%) ,0.001
Males, n (%) 649 (55%) 644 (55%) 0.849 12 (46%) 20 (38%) 0.515
Median age (IQR) 36 (29–45) 38 (30–46) 0.054 36 (31–37) 36 (27–41) 0.162
Unemployed, n (%) 999 (86%) 986 (85%) 0.496 23 (88%) 44 (85%) 0.399
Patient status at
registration, n (%)
New 852 (72%) 872 (74%) 0.369 6 (23%) 32 (62%) 0.001
Retreatment 324 (28%) 305 (26%) 20 (77%) 20 (38%)
Smear microscopy status at
registration, n (%)
,0.001 0.059
Positive 767 (65%) 664 (56%) 20 (77%) 30 (58%)
Negative 275 (23%) 493 (42%) 5 (19%) 22 (42%)
Unknown/not done 134 (11%) 20 (2%) 1 (4%) 0 (0)%)
HIV Status, n (%) ,0.001 0.598
Positive 667 (57%) 685 (58%) 15 (58%) 36 (69%)
Negative 299 (25%) 413 (35%) 6 (23%) 9 (17%)
Unknown 210 (18%) 79 (7%) 3 (19%) 7 (13%)
Median CD4 count among HIV-infected
individuals at TB diagnosis (IQR, cells/ml)**
185 (82–336) 176 (77–322) 0.773 297 (170–399) 174 (44–277) 0.082
On ART at TB diagnosis, n (% among HIV+) 101 (18%) 188 (29%) ,0.001 4 (27%) 23 (64%) 0.018
On cotrimoxazole at TB diagnosis,
n (% among HIV+)
456 (87%) 558 (84%) 0.320 24 (92%) 52 (88%) 0.599
Abbreviations: LPA, MTBDRplus line probe assay, IQR, interquartile range; HIV, human immunodeficiency virus; ART, antiretroviral therapy; TB, tuberculosis.
*p values are for comparison of the Before LPA period versus the After LPA period.
**CD4 cell counts within 6 months of TB diagnosis were recorded for 502 (75%) during the Before LPA period and 612 (89%) during the After LPA period.
doi:10.1371/journal.pone.0049898.t001
Figure 2. DST by patient category and study period. A breakdown of whether DST was performed or not, by study period (Before and After
LPA) and patient category (New versus Retreatment). Abbreviations: LPA, MTBDRplus line probe assay; DST, drug susceptibility testing.
doi:10.1371/journal.pone.0049898.g002
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median time to treatment was 79 days (IQR: 51–95, p 0.272). For
smear negative cases during the After LPA period, time to
treatment was 73.5 days (IQR: 43–94) compared to 89 days (IQR:
80–104, p 0.279) during the Before LPA period. The median time
from available DST result to appropriate MDR treatment start
(Figure 3A, time period 3) was 6 days longer during After LPA
period (22 days, [IQR: 12–48]) as compared to the Before LPA
period (16 days, [IQR: 7–32]), but the difference was not
statistically significant (p 0.188).
Laboratory turnaround times are presented in Figure 3B. The
median time from lab receipt of sputum to the start of DST, which
included any necessary primary MGIT culture, was longer in the
Before LPA period (27 days, [IQR: 21–34] compared to the After
LPA period (19 days, [IQR: 12–31], p,0.001). Smear positive
sputum samples during the After LPA period, which should not
require primary MGIT culture, had a median delay of 13 days to
start DST (IQR:9–16 days). Once DST was initiated, however,
results were available a median of 9 days earlier during the After
LPA period as compared to Before (p,0.001), with most results
available within one day during the After LPA period (median
time to results 0 days, IQR: 0–1).
Figure 4 shows the Kaplan-Meir curves for time to MDR
treatment by study period. Based on the observed MDR-TB
prevalence in the After LPA period, the number of MDR-TB
cases observed in the Before LPA period was likely an
underestimate. For exploratory purposes, we augmented the
number of MDR-TB cases during the Before LPA period to
match that observed during the After LPA period, by including 26
undetected MDR cases in the Before LPA period. In this modeled
Before LPA population of MDR-TB cases, only 44% were placed
on appropriate treatment.
MDR Patient Outcomes
The majority (64%) of MDR-TB patients during the Before
LPA period were on an MDR treatment regimen of pyrazinamide,
ethambutol, amikacin, ciprofloxacin and ethionimide, while
during the After LPA period, the majority (66%) were on a
regimen of pyrazinamide, kanamycin, ofloxacin, ethionimide and
terizidone.
Among treated MDR-TB patients in the After LPA period,
conversion of sputum cultures to negative occurred within 8
months of the initial clinic visit for 52% (95%CI:38–66), and the
median time to culture conversion was 5.7 months (IQR:4.6–7.3).
Median time to culture conversion for those in the Before LPA
period could not be calculated as only 27% (95%CI:10–44, p
0.036) converted their cultures by 8 months. By smear status, more
smear positive MDR cases in the After LPA period culture
converted (62% [95%CI: 42–79]) compared to during the Before
LPA period (22% [95%CI 6–48], p 0.008), while conversion
among smear negative cases differed between the two periods, but
the difference was not statistically significant (Before LPA: 80%
[95%CI: 28–99]; After LPA: 53% [95%CI:28–77], p 0.279).
During the Before LPA period eight deaths occurred by eight
months following the initial TB diagnosis visit (57/100 PY,
95%CI:29–114/100 PY), while there were 13 deaths during the
After LPA period (60/100 PY, 95%CI:35–104/100 PY). The
incidence rate ratio for mortality comparing the After LPA period
to the Before LPA period was 1.06 (95%CI:0.41–2.94, p 0.458).
The timing of deaths among MDR patients was different by study
period (Figure 5). Deaths during the After LPA period tended to
be earlier– six (46%) of the deaths occurred within two months of
registration, whereas in the Before LPA period there were no
deaths within two months of registration. The majority of deaths
during both study periods occurred among HIV-infected individ-
uals (Before LPA: 75%, (95%CI:45–100); After LPA: 77%,
(95%CI:54–100), p 0.917).
Discussion
In this setting, one with a high burden of both TB and HIV,
implementation of the expanded DST algorithm using
MTBDRplus improved several important outcomes. Twice the
Table 2. Drug resistance by study period.
Before LPA (n = 1176) After LPA (n = 1177) p-value
n % (95% CI) n % (95% CI)
MDR, all 26 2.2 (1.4–3.1) 52 4.4 (3.2–5.6) 0.003
New cases 6 0.7 (0.01–1.2) 32 3.7 (2.4–5.0) ,0.001
Retreatment cases 20 6.2 (3.6–8.8) 20 6.6 (3.8–9.4) 0.838
INH mono-resistance, all 28 2.4 (1.5–3.3) 49 4.2 (3.0–5.3) 0.015
New cases 9 1.1 (0.4–1.7) 35 4.0 (2.7–5.3) ,0.001
Retreatment cases 19 5.9 (3.3–8.4) 14 4.6 (2.2–6.9) 0.475
RIF mono-resistance, all 2 0.2 (0–0.4) 21 1.8 (1.0–2.5) ,0.001
New cases 0 0 13 1.5 (0.6–2.3) ,0.001
Retreatment cases 2 0.6 (0–1.5) 8 2.6 (0.8–4.4) 0.045
Any resistance*, all 56 4.8 (3.5–6.0) 121 10.3 (8.5–12.0) ,0.001
New cases 15 1.8 (0.8–2.6) 80 9.2 (7.2–11.1) ,0.001
Retreatment cases 41 12.7 (9.0–16.3) 41 13.4 (9.6–17.3) 0.767
MDR yield (among those tested) 10.4 (6.9–14.8) 5.2 (3.8–6.6) ,0.001
Any resistance yield (among those
tested)
20.3 (15.3–25.3) 12.2 (10.2–14.3) 0.001
Abbreviations: LPA, Hain MTBDRplus line probe assay; CI, confidence interval; MDR, multi-drug resistant; INH, isoniazid; RIF, rifampin.
*Any resistance refers to resistance to either INH or RIF, or both.
doi:10.1371/journal.pone.0049898.t002
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Figure 3. Time to treatment and drug susceptibility test turnaround times by study period. An illustration of critical events in the time to
MDR treatment and DST turnaround. Abbreviations: DST, drug susceptibility testing; LPA, MTBDRplus line probe assay; MDR, multi-drug resistant
tuberculosis; IQR, inter-quartile range.
doi:10.1371/journal.pone.0049898.g003
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number and proportion of MDR-TB cases was detected after
introduction of the expanded testing algorithm compared to
before, when DST was targeted to those thought to be at high risk
for drug resistance. Similar increases in case finding of mono-
resistance were also observed. Implementation of the expanded
algorithm with MTBDRplus resulted in a dramatic increase in the
application of DST among new TB cases and a substantial
increase in the number and proportion of new cases identified as
MDR or mono-resistant. Focusing DST on retreatment patients
has been justified by the argument that those without a history of
prior TB treatment are less likely to have resistance [14]. We
confirmed that the proportion of retreatment cases having MDR-
TB was higher than the proportion of new cases with MDR-TB
even after implementation of expanded DST. Importantly,
however, after implementation of expanded DST almost two-
thirds of total MDR-TB cases were new TB cases, demonstrating
the limitations of a DST testing strategy targeted to retreatment
TB cases. Since new patients with MDR-TB most likely reflect
acquisition through transmission, rather than resistance acquired
through inappropriate treatment, our results underline the
importance of control measures for prevention of MDR-TB
transmission. Rapid identification of mono-resistant TB cases is
also important in order to prevent serial acquisition of resistance,
and development of acquired MDR-TB.
MDR-TB patients in the After LPA period were almost twice as
likely to experience conversion of sputum cultures from positive to
negative by eight months following treatment initiation. Although
this beneficial effect may be partially due to a change in MDR
treatment regimen and an increase in ART coverage between the
two time periods, it nevertheless illustrates the value of identifying
MDR-TB cases through expanded testing so that more individuals
can be placed on appropriate treatment and transmission can be
interrupted.
Our results identified several processes that require strengthen-
ing. Using MTBDRplus rather than MGIT for DST resulted in a
shorter time from sputum collection to start of MDR treatment.
However, even among smear positive individuals (in whom
MTBDRplus can be performed directly on sputum), appropriate
MDR-TB therapy was initiated a median of two months after
initial sputum collection. Factors at the patient, clinic and
laboratory level can contribute to this delay in treatment. In this
study, the time from laboratory receipt of sputum to initiation of
DST using MTBDRplus for smear positive specimens was almost
two weeks, although we could not ascertain whether this delay was
due to the need to repeat DST on the primary MGIT isolate or
other factors. Whether performed directly on sputum or on
positive MGIT culture, laboratory testing by MTBDRplus proved
to be rapid–results were available the same day that testing was
initiated. If MTBDRplus were introduced in a context where
culture was not possible, we estimate that a significant proportion
(42%) of MDR-TB cases would be missed by performing the test
only on smear positive TB cases.
Troublingly, we found that after the introduction of the
expanded testing algorithm using MTBDRplus, it took longer to
initiate MDR treatment once DST results were known. During
both time periods, MDR-TB treatment was provided only at a 30-
bed inpatient unit that was often operating at capacity. Without
provisions for additional inpatient treatment capacity or alterna-
tives such as community-based MDR-TB treatment, this bottle-
Figure 4. Time to MDR treatment among MDR-TB patients, by study period. Kaplan-Meir curves for time from initial sputum collection to
MDR treatment by study period, including a modeled Before LPA period where the number of MDR-TB cases during the Before LPA period was
augmented to match that observed during the After LPA period. Abbreviations: LPA, MTBDRplus line probe assay; MDR, multidrug resistant
tuberculosis.
doi:10.1371/journal.pone.0049898.g004
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neck will blunt any potential gains of universal access to DST in
South Africa and elsewhere.
The before/after study design is an important limitation of this
study, as it is subject to bias by temporal trends. It is possible that
the higher prevalence of MDR-TB reported in the After LPA
period was a result of a true increase in disease occurring over time
in this community, rather than a reflection of increased detection
due to expanded DST. However, it is unlikely that a doubling in
MDR-TB prevalence occurred in the 18 months between study
periods. Further, the observed increase in MDR-TB prevalence
only among new TB cases and not among retreatment cases lends
credence to the conclusion that the rise in MDR-TB reflected
increased detection. Additional changes between the study periods
including increased uptake of HIV testing, an increase in ART
coverage and an improvement in MDR-TB treatment regimen
likely impacted MDR patient outcomes such as culture conversion
and mortality. Comparisons of these outcomes between study
periods should be made cautiously, as the number of MDR-TB
patients from this single health district does not allow for
meaningful adjustment to control for potential confounding
factors. Although the prevalence of MDR-TB is alarmingly high
in South Africa and other countries, it still remains a relatively rare
form of TB, and future studies examining the impact of MDR
diagnostics should include sufficient patients to examine these
important confounders.
This was an operational cohort study set within the context of
regular TB control program activities, using routinely collected
clinic and laboratory data. Diagnostic tests were conducted as
requested by clinicians and therefore may not have exactly
followed the recommended algorithm. These real world conditions
are ideal for illustrating the impact that this diagnostic test and
strategy can have in the very setting where implementation is
intended. Further, an operational study can identify problem
areas, such as the bottleneck in transitioning newly identified
MDR-TB patients into appropriate treatment, which if rectified
might lead to better patient outcomes.
Understanding the impact of MTBDRplus and the expanded
DST algorithm in this study depends on comparing patient
outcomes between the two study periods. As we illustrated, the
time to appropriate treatment observed for MDR-TB patients in
the Before LPA period is likely an underestimate, as perhaps half
of all MDR-TB cases during this period were missed, and
therefore time to MDR treatment was not observed. Likewise,
estimates of the impact of testing on mortality among MDR-TB
are subject to bias, as MDR-TB cases during the After LPA period
were more likely to be detected earlier, and thus mortality
occurring shortly after diagnosis would be correctly classified as
MDR-TB mortality rather than misclassified as non-MDR-TB
mortality as in the Before LPA period. These data represent a
conservative underestimate of the effect of expanded testing for
MDR-TB using the MTBDRplus.
The manufacturer has recently released the MTBDRplus
version 2.0, an improved version of the test which has shown
good accuracy in a validation study when used directly on both
smear negative and positive sputum samples [15]. This potentially
eliminates the need to first culture smear negative sputum samples,
which should translate to comparable turnaround times for both
smear negative and positive samples. Our data suggest that the
Figure 5. All-cause mortality by 8 months following initial registration among all MDR patients, by study period. Kaplan-Meir curves
for time from initial TB case registration to death by all causes among all MDR patients, by study period. Abbreviation: LPA, MTBDRplus line probe
assay.
doi:10.1371/journal.pone.0049898.g005
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impact of MTBDRplus version 1.0 was greater for smear positive
patients compared to smear negatives (reduced time to treatment
and increased culture conversion). The benefit to patients using
this newer version may exceed what is demonstrated here,
however further studies of version 2.0 in routine clinical practice
are needed.
Since this study was conducted, South Africa has revised their
TB diagnostic algorithm and is rolling out Xpert MTB/RIF
(Cepheid, Sunnyvale, CA) as the initial diagnostic in all those
suspected of TB [16]. Xpert MTB/RIF is a molecular assay
endorsed by the WHO [17] with good accuracy for TB
identification, rapid time to results (, two hours) and the ability
to simultaneously detect resistance to rifampicin as an indicator of
MDR-TB [18]. Xpert offers advantages over MTBDRplus: it can
be performed directly on both smear positive and negative
sputum, can be used to diagnose TB and rifampicin resistance,
and is technically much simpler, using a fully integrated sample
processing instrument [19]. Although the Xpert-based South
African algorithm maintains expanded access to DST, Xpert is
implemented at the point of the centralized laboratory, as with
MTBDRplus, which may blunt some of the assay’s potential
impact [20] and result in continued delays in time to results.
Additionally, Xpert does not test for isoniazid resistance, thus this
algorithm is likely to miss those with isoniazid mono-resistance.
Finally, without meaningful expansion of access to MDR-TB
treatment, Xpert will have no impact on decreasing the treatment
bottleneck observed here.
Overall, our study illustrates the mixture of successes and
challenges resulting from increased access to DST, and provides
important information to guide program strengthening. Com-
pared with the Before LPA strategy, under the expanded testing
strategy more MDR-TB cases and mono-resistant were identified,
the total time from initial sputum collection to initiation of
appropriate MDR-TB treatment was shorter, and a higher
proportion of MDR-TB patients experienced conversion of
sputum cultures to negative within eight months of treatment
initiation. However, time-to-appropriate MDR-TB treatment in
this setting was still measured in months rather than days. A rapid,
simple test that allows for decentralized testing has the potential to
meaningfully decrease the time to DST results [18]. As shown in
this study, an already overburdened public health system may not
be able to keep pace with an increase in MDR-TB resulting from
increased drug susceptibility testing, and expansion of MDR-TB
treatment facilities and strategies will be required. As more new
TB diagnostics are put into routine program use, assessments of
impact on clinical outcomes and the health system will be critical.
Diagnostic accuracy in the laboratory is arguably only a surrogate
marker for outcomes of real importance – reduction of morbidity
and mortality.
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